Snake Venom and Haemostasis – An Overview

European Haematology, 2008;2(1):7-11 DOI:
Citation European Haematology, 2008;2(1):7-11 DOI:

Venomous snakebites are still a public health problem in tropical countries. Even in metropolitan areas, such as Bangkok, green pit viper (Cryptelytrops albolabris and C. macrops) bites are still prevalent. As we are invading their territory, they adapt to live among humans in our backyards. With some exceptions, clinical syndromes of snakebites can be divided simply into two classes: elapid envenomation attacks neuromuscular junctions, causing muscular paralysis; viper envenomation targets the haemostatic system, resulting in bleeding disorders. Therefore, viper venoms are of great interest to haematologists. Vipers (Viperinae) are members of the snake family that develops the most advanced venom-injecting organs, the long sheathed fangs that can be folded like switchblades. Some vipers possess pit organs, infrared detectors for locating warm-blooded prey in the dark. This specialised subfamily is termed crotalidae (Pit viper), separating them from viperidae (True viper). Vipers found in the Americas are pit vipers, while African vipers are true vipers. Asia and Europe are homes to both subfamilies.
Viper Bites
Clinically, viper bites cause both local tissue damage and systemic effects: local tissue swelling, blisters from dermo-epidermal separation, ecchymoses and gangrene. Snake venom metalloprotease (SVMPs) have been implicated in these tissue injuries, both directly and indirectly via vascular damage1 and inflammatory responses.2 The most prominent systemic effects of pit viper venoms are towards fibrinogen and platelets. Although the venoms clot fibrinogen (thrombin-like effect) and activate platelets in vitro, these friable clots and platelet aggregates are rapidly cleared from circulation in vivo, resulting in hypofibrinogenaemia, termed defibrination syndrome, and thrombocytopenia.3 On the other hand, true vipers, such as Russell’s viper and Daboia russelii, activate common pathways of coagulation via factor X and V, causing bleeding from disseminated intravascular coagulation. Kinetics studies in humans showed that the viper venom is rapidly absorbed. However, the effects on blood may be delayed and prolonged as the half-life of viper venoms is over 24 hours.4 Antivenoms, the specific treatment of venomous snakebites, are polyclonal antibodies derived from horses or sheep. Older versions of antivenoms may cause potentially fatal early reactions mediated by complement activation from the immunoglobulin (Ig)-G (fragment, crystallisable) Fc portion.5,6 Current F (ab)’2 antivenoms in Thailand, the products of Queen Saovabha Memorial Institute, are pure and devoid of the Fc portion. A study revealed that the incidence of reactions is low (3.5%) and unpredictable by the intradermal test.7
  1. Gutiérrez JM, Rucavado A, Escalante T, Díaz C, Hemorrhage induced by snake venom metalloproteinases: biochemical and biophysical mechanisms involved in microvessel damage, Toxicon, 2005;45:997–1011.
  2. Laing GD, Clissa PB, Theakston RD, et al., Inflammatory pathogenesis of snake venom metalloproteinase-induced skin necrosis, Eur J Immunol, 2003;33:3458–63.
  3. Rojnuckarin P, Intragumtornchai T, Sattapiboon R, et al., The effects of green pit viper (Trimeresurus albolabris and Trimeresurus macrops) venom on the fibrinolytic system in human, Toxicon, 1999;37:743–55.
  4. Rojnuckarin P, Banjongkit S, Chantawibun W, et al., Green pit viper (Trimeresurus albolabris and T. macrops) venom antigenaemia and kinetics in humans, Trop Doct, 2007;37: 207–10.
  5. Malasit P, Warrell DA, Chanthavanich P, et al., Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites, Br Med J (Clin Res Ed), 1986; 292:17–20.
  6. Rojnuckarin P, Mahasandana S, Intragumthornchai T, et al., Prognostic factors of green pit viper bites, Am J Trop Med Hyg, 1998;58:22–5.
  7. Thiansookon A, Rojnuckarin P, Low incidence of early reactions to horse-derived F(ab')(2) antivenom for snakebites in Thailand, Acta Trop, 2008;105:203–5.
  8. Rojnuckarin P, Chanthawibun W, Noiphrom J, et al., A randomized, double-blind, placebo-controlled trial of antivenom for local effects of green pit viper bites, Trans R Soc Trop Med Hyg, 2006;100:879–84.
  9. Chotenimitkhun R, Rojnuckarin P, Systemic antivenom and skin necrosis after green pit viper bites, Clin Toxicol (Phila), 2008; 46:122–5.
  10. Gutiérrez JM, León G, Rojas G, et al., Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom, Toxicon, 1998;36:1529–38.
  11. Fry BG, Vidal N, Norman JA, et al., Early evolution of the venom system in lizards and snakes, Nature, 2006;439:584–8.
  12. Reza MA, Swarup S, Kini RM, Structure of two genes encoding parallel prothrombin activators in Tropidechis carinatus snake: gene duplication and recruitment of factor X gene to the venom gland, J Thromb Haemost, 2007;5:117–26.
  13. Nakashima K, Nobuhisa I, Deshimaru M, et al., Accelerated evolution in the protein-coding regions is universal in crotalinae snake venom gland phospholipase A2 isozyme genes, Proc Natl Acad Sci U S A, 1995;92:5605–9.
  14. Hartig GR, Tran TT, Smythe ML, Intramolecular disulphide bond arrangements in nonhomologous proteins, Protein Sci, 2005;14: 474–82.
  15. Fox JW, Serrano SM, Insights into and speculations about snake venom metalloproteinase (SVMP) synthesis, folding and disulfide bond formation and their contribution to venom complexity, FEBS J, 2008;275:3016–30.
  16. Navdaev A, Dörmann D, Clemetson JM, Clemetson KJ, Echicetin, a GPIb-binding snake C-type lectin from Echis carinatus, also contains a binding site for IgMkappa responsible for platelet agglutination in plasma and inducing signal transduction, Blood, 2001;97:2333–41.
  17. Crawley JT, Zanardelli S, Chion CK, Lane DA, The central role of thrombin in hemostasis, J Thromb Haemost, 2007;5(Suppl. 1): 95–101.
  18. Huntington JA, Molecular recognition mechanisms of thrombin, J Thromb Haemost, 2005;3:1861–72.
  19. Au LC, Lin SB, Chou JS, et al., Molecular cloning and sequence analysis of the cDNA for ancrod, a thrombin-like enzyme from the venom of Calloselasma rhodostoma, Biochem J, 1993;294: 387–90.
  20. Itoh N, Tanaka N, Mihashi S, Yamashina I, Molecular cloning and sequence analysis of cDNA for batroxobin, a thrombin-like snake venom enzyme, J Biol Chem, 1987;262:3132–5.
  21. Rojnuckarin P, Muanpasitporn C, Chanhome L, et al., Molecular cloning of novel serine proteases and phospholipases A2 from green pit viper (Trimeresurus albolabris) venom gland cDNA library, Toxicon, 2006;47:279–87.
  22. Amiconi G, Amoresano A, Boumis G, et al., A novel venombin B from Agkistrodon contortrix contortrix: evidence for recognition properties in the surface around the primary specificity pocket different from thrombin, Biochemistry, 2000; 39:10294–10308.
  23. Komori Y, Nikai T, Ohara A, et al., Effect of bilineobin, a thrombin-like proteinase from the venom of common cantil (Agkistrodon bilineatus), Toxicon, 1993;31:257–70.
  24. Serrano SM, Mentele R, Sampaio CA, Fink E, Purification, characterization, and amino acid sequence of a serine proteinase, PA-BJ, with platelet-aggregating activity from the venom of Bothrops jararaca, Biochemistry, 1995;34:7186–93.
  25. Kisiel W, Kondo S, Smith KJ, et al., Characterization of a protein C activator from Agkistrodon contortrix contortrix venom, J Biol Chem, 1987;262:12607–13.
  26. Tokunaga F, Nagasawa K, Tamura S, et al., The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences, J Biol Chem, 1988;263:17471–81.
  27. Muanpasitporn C, Rojnuckarin P, Expression and characterization of a recombinant fibrinogenolytic serine protease from green pit viper (Trimeresurus albolabris) venom, Toxicon, 2007;49:1083–9.
  28. Parry MA, Jacob U, Huber R, et al., The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases, Structure, 1998; 6:1195–1206.
  29. Murakami MT, Arni RK, Thrombomodulin-independent activation of protein C and specificity of hemostatically active snake venom serine proteinases: crystal structures of native and inhibited Agkistrodon contortrix contortrix protein C activator, J Biol Chem, 2005;280:39309–15.
  30. Weisel JW, Which knobs fit into which holes in fibrin polymerization?, J Thromb Haemost, 2007;5:2340–43.
  31. Guo Y, Zuo YF, Wang QZ, et al., Meta-analysis of defibrase in treatment of acute cerebral infarction, Chin Med J (Engl), 2006; 119:662–8.
  32. Hennerici MG, Kay R, Bogousslavsky J, et al., ESTAT investigators, Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial, Lancet, 2006;368:1871–8.
  33. Laing GD, Moura-da-Silva AM, Jararhagin and its multiple effects on hemostasis, Toxicon, 2005;45:987–96.
  34. Guan AL, Retzios AD, Henderson GN, Markland FS Jr, Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (Agkistrodon contortrix contortrix), Arch Biochem Biophys, 1991;289: 197–207.
  35. Andrews RK, Gardiner EE, Asazuma N, et al., A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI, J Biol Chem, 2001;276: 28092–7.
  36. Nishida S, Fujita T, Kohno N, et al., cDNA cloning and deduced amino acid sequence of prothrombin activator (ecarin) from Kenyan Echis carinatus venom, Biochemistry, 1995;34:1771–8.
  37. Takeda S, Igarashi T, Mori H, Crystal structure of RVV-X: an example of evolutionary gain of specificity by ADAM proteinases, FEBS Lett, 2007;581:5859–64.
  38. Toombs CF, Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis, Haemostasis, 2001;31: 141–7.
  39. Swenson S, Markland FS Jr, Snake venom fibrin(ogen)olytic enzymes, Toxicon, 2005;45:1021–39.
  40. Scarborough RM, Rose JW, Hsu MA, et al., Barbourin. A GPIIb- IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri, J Biol Chem, 1991;266:9359–62.
  41. Suehiro K, Smith JW, Plow EF, The ligand recognition specificity of beta3 integrins, J Biol Chem, 1996;271:10365–71.
  42. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S, Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site, Blood, 1997;90: 1565–75.
  43. Singhamatr P, Rojnuckarin P, Molecular cloning of albolatin, a novel snake venom metalloprotease from green pit viper (Trimeresurus albolabris), and expression of its disintegrin domain, Toxicon, 2007;50:1192–1200.
  44. Calvete JJ, Marcinkiewicz C, Monleón D, et al., Snake venom disintegrins: evolution of structure and function, Toxicon, 2005; 45:1063–74.
  45. Takeda S, Igarashi T, Mori H, Araki S, Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique Cshaped scaffold, EMBO J, 2006;25:2388–96.
  46. Calvete JJ, Marcinkiewicz C, Sanz L, KTS and RTS-disintegrins: anti-angiogenic viper venom peptides specifically targeting the alpha 1 beta 1 integrin, Curr Pharm Des, 2007;13:2853–9.
  47. Yang RS, Tang CH, Chuang WJ, et al., Inhibition of tumor formation by snake venom disintegrin, Toxicon, 2005;45: 661–9.
  48. Zhou Q, Nakada MT, Arnold C, et al., Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis, Angiogenesis, 1999;3:259–69.
  49. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy, N Engl J Med, 1998;339:436–43.
  50. Swenson S, Ramu S, Markland FS, Anti-angiogenesis and RGDcontaining snake venom disintegrins, Curr Pharm Des, 2007;13: 2860–71.
  51. Zelensky AN, Gready JE, The C-type lectin-like domain superfamily, FEBS J, 2005;272:6179–217.
  52. Morita T, C-type lectin-related proteins from snake venoms, Curr Drug Targets Cardiovasc Haematol Disord, 2004;4:357–73.
  53. Atoda H, Hyuga M, Morita T, The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E, J Biol Chem, 1991;266:14903–11.
  54. Kowalska MA, Tan L, Holt JC, et al., Alboaggregins A and B. Structure and interaction with human platelets, Thromb Haemost, 1998;79:609–13.
  55. Murakami MT, Zela SP, Gava LM, et al., Crystal structure of the platelet activator convulxin, a disulfide-linked alpha4beta4 cyclic tetramer from the venom of Crotalus durissus terrificus, Biochem Biophys Res Commun, 2003;310:478–82.
  56. Morita T, Structures and functions of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-, procoagulant-, and platelet-modulating activities, Toxicon, 2005;45:1099–1114.
  57. Fukuda K, Mizuno H, Atoda H, Morita T, Crystal structure of flavocetin-A, a platelet glycoprotein Ib-binding protein, reveals a novel cyclic tetramer of C-type lectin-like heterodimers, Biochemistry, 2000;39:1915–23.
  58. Atoda H, Ishikawa M, Mizuno H, Morita T, Coagulation factor Xbinding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein, Biochemistry, 1998;37:17361–70.
  59. Arpijuntarangkoon J, Rojnuckarin P, Muanpasitporn C, et al., Molecular cloning and sequence analysis of alboaggregin B, Platelets, 2007;18:266–72.
  60. Dörmann D, Clemetson JM, Navdaev A, et al., Alboaggregin A activates platelets by a mechanism involving glycoprotein VI as well as glycoprotein Ib, Blood, 2001;97:929–36.
  61. Du Xiao-Yan, Magnenat E, Wells TN, Clemetson KJ, Alboluxin, a snake C-type lectin from Trimeresurus albolabris venom is a potent platelet agonist acting via GPIb and GPVI, Thromb Haemost, 2002;87:692–8.
  62. Lee WH, Du XY, Lu QM, et al., Stejnulxin, a novel snake C-type lectin-like protein from Trimeresurus stejnegeri venom is a potent platelet agonist acting specifically via GPVI, Thromb Haemost, 2003;90:662–71.
  63. Chang CH, Chung CH, Kuo HL, et al., The highly specific platelet glycoprotein (GP) VI agonist trowaglerix impaired collageninduced platelet aggregation ex vivo through matrix metalloproteinase-dependent GPVI shedding, J Thromb Haemost, 2008;6:669–76.
  64. Maita N, Nishio K, Nishimoto E, et al., Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins, J Biol Chem, 2003;278: 37777–81.
  65. Zingali RB, Ferreira MS, Assafim M, et al., Bothrojaracin, a Bothrops jararaca snake venom-derived (pro)thrombin inhibitor, as an anti-thrombotic molecule, Pathophysiol Haemost Thromb, 2005;34:160–63.
  66. Nevalainen TJ, Graham GG, Scott KF, Antibacterial actions of secreted phospholipases A2, Biochim Biophys Acta, 2008;1781: 1–9.
  67. Kini RM, Structure-function relationships and mechanism of anticoagulant phospholipase A2 enzymes from snake venoms, Toxicon, 2005;45:1147–61.
  68. Fujisawa D, Yamazaki Y, Lomonte B, Morita T, Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region, Biochem J, 2008;411:515–22.